Trends in Endophthalmitis Associated with Intravitreal Injection of Anti-VEGF Agents at a Tertiary Referral Center

the Endophthalmitis/Anti-VEGF Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND AND OBJECTIVE: To report the incidence and clinical features of infectious endophthalmitis after intravitreal (IV) injection of anti-vascular endothelial growth factor inhibitors (VEGF) between 2018 and 2020 and to compare to prior rates. PATIENTS AND METHODS: Retrospective analysis of patients with endophthalmitis after anti-VEGF IV injections treated at Bascom Palmer Eye Institute between January 1, 2018, and December 31, 2020. RESULTS: Between 2018 and 2020, the rate of clinically diagnosed endophthalmitis was 0.014% (10/71,858) and of culture-positive was 0.008% (6/71,858). Clinically diagnosed endophthalmitis rates per injection were: aflibercept (0.022%); ranibizumab (0.019%); bevacizumab (0%); and brolucizumab (0%). Clinically diagnosed endophthalmitis rates were similar in the present study compared to those from 2005 to 2017 (P = .84). Fifteen eyes were diagnosed with endophthalmitis (10 in-house, five external referrals). Of culture-positive eyes, the organisms were coagulase-negative Staphylococcus (8/11), Streptococcus species (2/11), and Abiotrophia defectiva (1/11). A universal face-masking policy in 2020 did not lower infection rates (P = .73). CONCLUSION: Endophthalmitis rates after IV anti-VEGF remain low and are similar to prior reports.

Original languageEnglish (US)
Pages (from-to)319-326
Number of pages8
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume52
Issue number6
DOIs
StatePublished - Jun 2021

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint

Dive into the research topics of 'Trends in Endophthalmitis Associated with Intravitreal Injection of Anti-VEGF Agents at a Tertiary Referral Center'. Together they form a unique fingerprint.

Cite this